Back to top

Analyst Blog

Astellas Pharma, Inc. (ALPMY) recently announced a deal with Ambrx Inc. for the discovery and development of novel antibody drug conjugates (ADC).

Terms of the Deal

As per the agreement, Ambrx is entitled to an upfront payment of $15 million. Moreover, Ambrx could earn up to an additional $285 million on the achievement of research, development, regulatory and sales-based milestones for a number of targets for ADCs in oncology.

In return, Astellas will have global rights for the development and commercialization of ADCs for oncology. A part of the milestones plus royalties on any net sales will depend on the eventual success of products developed under this partnership.

Our Take

We are positive on this collaboration which should help expand Astellas’ capability in the development of ADCs for oncology.

Astellas currently has AGS-16M8F/AGS-16C3F for renal cancer, ASG-5ME for prostate cancer as well as pancreatic cancer and ASG-22ME for solid tumors in its pipeline. All three are in phase I. In Jan 2013, data was announced from a phase I clinical study evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA).

ADCs have been attracting a lot of interest in the recent past with major companies entering into collaborations. Seattle Genetics (SGEN - Snapshot Report) is a key player in this field and has collaborations with many companies like Roche Holding AG's (RHHBY - Analyst Report) Genentech and Astellas for the development of ADCs.

Astellas carries a Zacks Rank #4 (Sell). Currently WuXi Pharma Tech (Cayman) Inc. (WX - Snapshot Report) looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.75 +5.63%
BANCO DO BR… BDORY 14.70 +5.38%
EQT MIDSTRE… EQM 98.33 +3.58%
AIR INDUSTR… AIRI 9.90 +3.23%
WEATHERFORD… WFT 23.66 +3.23%